Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

sus temsirolimus in relapsed or refractory  MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a mono-therapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression free survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL. The primary endpoint of the study is progression free survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen, is open and Janssen plans to enroll 110 patients worldwide.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... The first product launch from start-up Hurley Research ... What sets Droidles completely apart from other stand alone ... to communicate, share code with each other and evolve ... invention is the system,” said Hurley Research founder Jay ... their own, both physically and on the internet." Remote ...
    (Date:7/29/2014)... The prestigious "Discovery or Exploration in ... awarded to Juliana Hillis and Kaylie O’Connell, students at ... “From an Egg, Everything: America’s First IVF Baby". This ... the National History Day program during a week-long final ... in Washington, D.C. , The growing popularity of the ...
    (Date:7/29/2014)... CA (PRWEB) July 29, 2014 ... medical devices, and cloud based eClinical technologies, have been ... Device Online. These follow a long line of white ... profile publications including Life Science Leader, Pharmaceutical Online, and ... Clinovo provided a paper by CTO Marc Desgrousilliers, ...
    (Date:7/29/2014)... , July 29, 2014 ... System (LBS) zur Erfassung biologischer Daten in ... entwickelt und patentiert. Das LBS nimmt gleichzeitig ... Koronararterie des Patienten und sucht erhöhte biologische ... das Potenzial, die Entdeckung und Entwicklung neuer ...
    Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
    ... Pharmaceutical and ... Biotech Industries, ... short-term and long-term biomaterials storage, sample,management and cold chain logistics, ... inaugural,Biorepositories 2008, the only U.S.-based event for the pharmaceutical and,biotech ...
    ... portfolio, CORAL GABLES, Fla., June 23 ... pharmaceutical company specializing in,dermatology, today announced it ... which Stiefel Laboratories will acquire Barrier Therapeutics,Inc. ... a two-step,transaction, a tender offer followed by ...
    ... JOLLA, Calif., June 23 TorreyPines Therapeutics,Inc. (Nasdaq: ... Kurtz, President and,Chief Executive Officer, will present data ... safety, tolerability and efficacy of three doses,of tezampanel ... the,50th Annual Scientific Meeting of the American Headache ...
    Cached Biology Technology:BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2Barrier Therapeutics to Merge Into Stiefel Laboratories 2Barrier Therapeutics to Merge Into Stiefel Laboratories 3Barrier Therapeutics to Merge Into Stiefel Laboratories 4Barrier Therapeutics to Merge Into Stiefel Laboratories 5TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society 2
    (Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
    (Date:7/29/2014)... Research and Markets  has announced the ... Market 2014-2018" report to their offering. ... term BI refers to applications and technologies that are ... about a company,s operations. BI help organizations to acquire ... example, metrics on sales, production, and internal operations. ...
    (Date:7/29/2014)... Swimming microorganisms, such as bacteria and spermatozoa, are subjected ... forces exerted by the surrounding fluid. Such low-level ... found that the direction of propulsion made possible by ... viscoelastic fluid. These findings have been published in ... Energies and Atomic Energy Commission (CEA), in Le Barp, ...
    Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
    ... to interact with the genes her unborn child inherits and ... research funded by the Wellcome Trust and the British Heart ... Molecular Genetics , suggests that mothers who eat a high ... the health of their offspring at risk. Congenital heart ...
    ... a new means of determining the sex of skeletal human ... the wake of disasters, the studying of ancient remains and ... able to determine the sex of skeletal remains by visually ... coxa. "This technique is accurate, but is not without its ...
    ... Ga. - Robots that revolutionized gynecologic and urologic surgery in ... least a portion of their diseased thyroid gland without the ... just under the Adam,s apple and controls the body,s metabolic ... cancerous disease can more than double its size. Dr. David ...
    Cached Biology News:Maternal diet and genes interact to affect heart development 2Maternal diet and genes interact to affect heart development 3Hips don't lie: Researchers find more accurate technique to determine sex of skeletal remains 2Robots preclude neck incision for thyroid surgery 2
    ... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
    Determine relative degree of protein binding to phosphoinositides...
    ... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
    Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
    Biology Products: